To address whether this pathway is essential for this event in breast cancer cells, we assessed the impact of PKC catalytic activity using two ATP-competitive inhibitors: BIM (pan-PKC inhibitor) and C27 (PKC-θ-specific inhibitor), which we have previously shown to inhibit EMT and CSC formation in breast cancer [28]. The gene discussed is PRRT2; the disease is breast carcinoma.